Overview

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

Status:
Completed
Trial end date:
2014-04-24
Target enrollment:
Participant gender:
Summary
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Collaborator:
The TIMI Study Group
Treatments:
Darapladib